Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
The novel class of USP1 inhibitors opens up new frontiers for the treatment of cancers and diabetes
Valuable Targets
10 min read
The novel class of USP1 inhibitors opens up new frontiers for the treatment of cancers and diabetes
17 July 2023
the discovery and development of USP1 inhibitors certainly open up new frontiers for the treatment of a variety of diseases, including cancer, diabetes, and potentially even more.
Read →
No sequence will be left unexplored with Patsnap Bio!
Bio Sequence
4 min read
No sequence will be left unexplored with Patsnap Bio!
17 July 2023
In order to address the risk of missed detection brought by degenerate sequences, the Patsnap Engineering team utilizes its self-developed NLP, CV, entity recognition, anaphora resolution and other technologies to construct a deep learning model.
Read →
The GLP-1R plus strategy for curbing the obesity epidemic
Hot Spotlight
5 min read
The GLP-1R plus strategy for curbing the obesity epidemic
14 July 2023
this approach brings new hope that we can finally address the growing concern of obesity worldwide.
Read →
Cdc42 provides a new target for treating Alzheimer’s Disease
Cdc42 provides a new target for treating Alzheimer’s Disease
13 July 2023
the small G protein family member, Cdc42, plays an important role in the progression of Alzheimer's disease.
Read →
Discovery of a New Drug for Inflammatory and Autoimmune Diseases: TAK-279
Drug Insights
4 min read
Discovery of a New Drug for Inflammatory and Autoimmune Diseases: TAK-279
12 July 2023
TAK-279, which is a highly selective inhibitor of TYK2 enzymatic activity.
Read →
Organoid-On-Chips: A Potential Game Changer for Clinical Studies
Advanced Tech.
5 min read
Organoid-On-Chips: A Potential Game Changer for Clinical Studies
12 July 2023
HRS-1893 works through a special mechanism that inhibits myocardial excessive contraction and is intended for the treatment of hypertrophic cardiomyopathy and heart failure caused by myocardial hypertrophy.
Read →
Behind the Approval of Lecanemab: A Decade of Hardship Cannot Dampen Passion
Drug Insights
6 min read
Behind the Approval of Lecanemab: A Decade of Hardship Cannot Dampen Passion
11 July 2023
As the only Alzheimer's drug fully approved by the FDA in the last 20 years, it may genuinely bring a ray of hope to patients plagued by the disease worldwide.
Read →
Overview of the Development Progress of TIGIT Drug Target
Overview of the Development Progress of TIGIT Drug Target
11 July 2023
TIGIT, a major immune checkpoint molecule, is expressed on the surface of T cells and natural killer (NK) cells.
Read →
AbbVie: The Exploration Journey of an Immunology Titan
R&D Pipeline
10 min read
AbbVie: The Exploration Journey of an Immunology Titan
11 July 2023
What led to AbbVie's present success? And what lessons can other pharmaceutical companies learn from its success?
Read →
The Magic Bullets of Cancer Treatment: ADCs and Their Journey from Concept to Clinic
Advanced Tech.
5 min read
The Magic Bullets of Cancer Treatment: ADCs and Their Journey from Concept to Clinic
11 July 2023
Unlike conventional chemotherapy, which can damage healthy cells, ADCs are intended to target and kill tumor cells while sparing healthy cells.
Read →
Bringing KRAS G12C Inhibitors to Market: The Game Is On
Bringing KRAS G12C Inhibitors to Market: The Game Is On
11 July 2023
AZD4747, that shows promise in treating tumors with the KRAS G12C mutation.
Read →
Discussing AstraZeneca's Brain-penetrating KRAS Inhibitor
Drug Insights
8 min read
Discussing AstraZeneca's Brain-penetrating KRAS Inhibitor
10 July 2023
KRAS G12C inhibitors that can penetrate the brain have a differentiated clinical advantage.
Read →